Roche NimbleGen Announces Frank Pitzer as New CEO

Roche NimbleGen Announces Frank Pitzer as New CEO

MADISON, Wis.--(BUSINESS WIRE)--Mar 25, 2010 - Roche NimbleGen (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY), a global leader in microarray tools for genetic discovery and analysis, announced today that Frank Pitzer has been appointed as CEO. Dr. Pitzer's extensive background and experience of over eight years at Roche will be instrumental in guiding the company through its next stage of growth. With his successful track record in several key management positions within Roche Diagnostics, he brings a wealth of organizational, commercial, and relevant operating experience in key areas impacting the genomics and life science industry today.

Dr. Pitzer most recently served as Head of Divisional Quality and Regulatory Affairs reporting directly to the CEO of Roche Diagnostics and was also an active member of the Diagnostics Executive Committee (DEC). In addition to his extensive management experience and background at Roche, Dr. Pitzer brings a broad scientific perspective having earned a PhD in Biology from Max Planck Institute for Biochemistry.

"We are extremely excited to announce Dr. Frank Pitzer as the CEO of Roche NimbleGen and look forward to expanding the company's position as a leading genomics solution provider," stated Manfred Baier, Head of Roche Applied Science. "Frank's leadership skills and extensive experience in the life science industry make him the perfect fit to guide Roche NimbleGen through the next stages of growth. His valuable insight and outstanding management experience will further entrench the company as a leading manufacturer of microarray technologies."

For more information on Roche NimbleGen, visit

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: